Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.543
+0.002 (0.33%)
At close: Jun 26, 2026, 4:00 PM EDT
0.535
-0.008 (-1.55%)
After-hours: Jun 26, 2026, 6:32 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,946,785
Market Cap
18.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Quince Therapeutics | 38 |
| Palatin Technologies | 29 |
| Moleculin Biotech | 17 |
| Atossa Therapeutics | 16 |
| Lipocine | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
KTTA News
- 12 days ago - Pasithea Therapeutics announces amendments to PAS-004 clinical study - TheFly
- 12 days ago - Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial - GlobeNewsWire
- 13 days ago - Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - GlobeNewsWire
- 13 days ago - Pasithea Therapeutics Transcript: Transcript - Transcripts
- 26 days ago - Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA - TheFly
- 26 days ago - Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) - GlobeNewsWire
- 4 weeks ago - Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis - TheFly
- 7 weeks ago - Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer - TheFly